Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-03-18, Stock:LLY, The news for the past five days is as follows:
2019-03-11: NEWS1: Health Care Sector Update for 03/11/2019: JNJ,ELAN,LLY,AXGT,CRON,CRON.TO.NEWS2: Health Care Sector Update for 03/11/2019: JNJ,ELAN,LLY,AXGT,CRON,CRON.TO.NEWS3: Elanco Animal Health Begins Trading After Eli Lilly Split.NEWS4: Health Care Sector Update for 03/11/2019: ELAN,LLY,AXGT,CRON,CRON.TO.NEWS5: Health Care Sector Update for 03/11/2019: ELAN,LLY,AXGT,CRON,CRON.TO.NEWS6: Stocks - Dow Reverses Early Losses to End Higher as Tech Rallies.NEWS7: The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's.NEWS8: The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's.NEWS9: S&P 500 Movers: BA, WDC.NEWS10: S&P 500 Movers: BA, WDC.NEWS11: The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's.NEWS12: Lilly Announces Preliminary Results of Elanco Exchange Offer.
2019-03-12: NEWS1: Eli Lilly (LLY) Flat As Market Gains: What You Should Know.NEWS2: Eli Lilly’s Latest Move Proves the American Healthcare System Is Broken.NEWS3: Eli Lilly’s Latest Move Proves the American Healthcare System Is Broken.NEWS4: BioNtech hires banks for IPO worth up to $800 million - sources.NEWS5: Biontech stock offering could be worth as much as $800 million-sources.NEWS6: Allergan Announces FDA Acceptance of Migraine Candidate NDA.NEWS7: Allergan Announces FDA Acceptance of Migraine Candidate NDA.NEWS8: Eli Lilly Could Sustain Industry-Leading Growth, Says Bullish JPMorgan.NEWS9: Eli Lilly’s Latest Move Proves the American Healthcare System Is Broken.NEWS10: See what the IHS Markit Score report has to say about Eli Lilly and Co..NEWS11: Allergan Announces FDA Acceptance of Migraine Candidate NDA.NEWS12: Why Eli Lilly Stock Fell Yesterday.NEWS13: Here are the biggest analyst calls of the day: Tesla, Boeing, Coca-Cola, Monster Beverage, Eli Lilly.NEWS14: Here are the biggest analyst calls of the day: Tesla, Boeing, Coca-Cola, Monster Beverage, Eli Lilly.NEWS15: Lilly's combo therapy succeeds in late-stage lung cancer study.NEWS16: Lilly's combo treatment meets main goal in lung cancer late-stage study.NEWS17: Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer.NEWS18: Dicerna Pharmaceuticals Inc (DRNA) Q4 2018 Earnings Conference Call Transcript.
2019-03-13: NEWS1: After Hours Most Active for Mar 13, 2019 :  MSFT, LLY, F, CMCSA, PFE, FOX, CTL, HPQ, PCG, AMD, AAPL, ENDP.NEWS2: After Hours Most Active for Mar 13, 2019 :  MSFT, LLY, F, CMCSA, PFE, FOX, CTL, HPQ, PCG, AMD, AAPL, ENDP.NEWS3: Lilly's Cyramza Successful in Phase III First-Line NSCLC Study.NEWS4: Lilly's Cyramza Successful in Phase III First-Line NSCLC Study.NEWS5: Lilly's Cyramza Successful in Phase III First-Line NSCLC Study.NEWS6: IVW, AMZN, LLY, CRM: Large Outflows Detected at ETF.NEWS7: IVW, AMZN, LLY, CRM: Large Outflows Detected at ETF.NEWS8: FDA medical adviser: 'Congress is owned by pharma'.NEWS9: Lilly Announces Final Results of Elanco Exchange Offer.
2019-03-14: NEWS1: After Hours Most Active for Mar 14, 2019 :  GCP, LLY, HPQ, F, PFE, ACB.NEWS2: After Hours Most Active for Mar 14, 2019 :  GCP, LLY, HPQ, F, PFE, ACB.NEWS3: Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades.
2019-03-15: NEWS1: Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others.NEWS2: Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others.NEWS3: The Case Against Pfizer Stock and the Rest of the Industry.NEWS4: The Case Against Pfizer Stock and the Rest of the Industry.NEWS5: Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others.NEWS6: The Case Against Pfizer Stock and the Rest of the Industry.

Answer: Rise